Related Articles
Colcrys Approval Triggers Questions
Some rheumatologists question the depth of research and the approval’s implications for patient access
The Unapproved-Drugs Initiative Is Coming to an End
On Friday, Nov. 20, 2020, the U.S. Department of Health and Human Services (HHS) published a Notice through the Federal Register announcing the withdrawal of guidance documents that established the Unapproved Drugs Initiative. This Notice brings to an end a 14-year-old program that has been blamed for significantly contributing to the rising cost of some…
Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
International Study Finds Colchicine Promising as Outpatient Treatment for COVID-19
One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.